Description: Brii Biosciences Limited engages in the development of medicines for the treatment of infectious and central nervous system diseases. It develops product candidates for the treatment of chronic hepatitis B infection, human immunodeficiency virus, MDR/XDR Gram, MDR TB mycobacteria, and Covid-19 diseases; and postpartum depression and major depressive disorder diseases. The company was incorporated in 2017 and is based in Beijing, China.
Home Page: www.briibio.com
Building 7, International Science Park
Beijing,
100192
China
Phone:
Officers
| Name | Title |
|---|---|
| Dr. Zhi Hong Ph.D. | Co-founder, Executive Chairman of the Board & CEO |
| Dr. Ankang Li C.F.A., J.D., Ph.D. | Chief Financial & Strategy Officer, Company Secretary and Executive Director |
| Dr. Eleanor de Groot Ph.D. | Chief Technology Officer |
| Dr. Brian Alvin Johns Ph.D. | Chief Scientific Officer |
| Sarah Qiu | Associate Director of Investor Relations |
| Ms. Karen Del Barrio Neuendorff | Chief People Officer & Head of Human Resources |
| Mr. Coy Stout | Head of Patient Advocacy |
| Dr. Lianhong Xu Ph.D. | Head of Discovery |
| Dr. Qing Zhu Ph.D. | Head of China Research & Development |
| Dr. David Margolis M.D., M.P.H. | Chief Medical Officer |
Exchange: PINK
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 0.2257 |
| Price-to-Sales TTM: | 3.5809 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 95 |